Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: Biotech Jim who wrote (2817)	12/12/2012 12:36:29 PM
From: scaram(o)uche	2 Recommendations Respond to of 3202

>> Would love to have his view on this, but I do not << Try drugs and alcohol? Please?

To: Biotech Jim who wrote (2817)	12/12/2012 1:53:40 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 3202

issued..... patft.uspto.gov filed, includes JAK3-specific methods, filed 1/12/05.... maybe VRTX-relevant?........ appft.uspto.gov First blush, couldn't find anything blocked by the JAK2 crystal work (priority date, 10/11/05), but it takes a chemist to wade through this stuff... I'm always lost. Please note that these search results include jak2 as a search term.......... haven't checked to see if breadth can be had.

To: Biotech Jim who wrote (2817)	1/10/2013 1:08:41 PM
From: scaram(o)uche	Respond to of 3202

I think that Peter found it, GILD's tipping point, when he pointed to the TBK1 activity of cyt387. Several recent indicators that it's an interesting target. Not related to incy directly, but it's on my clipboard...... Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance Novartis Institutes for Biomedical Research, Emeryville, California 94608, USA Meghna Das Thakur, Fernando Salangsang, Nancy K. Pryer & Darrin D. Stuart Helen Diller Family Comprehensive Cancer Center & Department of Cellular & Molecular Pharmacology, University of California San Francisco, California 94143-0128, USA Allison S. Landman & Martin McMahon Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139, USA William R. Sellers Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, 8091 Zürich, Switzerland Mitchell P. Levesque & Reinhard Dummer Nature(2013)doi:10.1038/nature11814Received 19 May 2012 Accepted 29 November 2012 Published online 09 January 2013 Mutational activation of BRAF is the most prevalent genetic alteration in human melanoma, with?=50% of tumours expressing the BRAF(V600E) oncoprotein1, 2. Moreover, the marked tumour regression and improved survival of late-stage BRAF-mutated melanoma patients in response to treatment with vemurafenib demonstrates the essential role of oncogenic BRAF in melanoma maintenance3, 4. However, as most patients relapse with lethal drug-resistant disease, understanding and preventing mechanism(s) of resistance is critical to providing improved therapy5. Here we investigate the cause and consequences of vemurafenib resistance using two independently derived primary human melanoma xenograft models in which drug resistance is selected by continuous vemurafenib administration. In one of these models, resistant tumours show continued dependency on BRAF(V600E)MEKERK signalling owing to elevated BRAF(V600E) expression. Most importantly, we demonstrate that vemurafenib-resistant melanomas become drug dependent for their continued proliferation, such that cessation of drug administration leads to regression of established drug-resistant tumours. We further demonstrate that a discontinuous dosing strategy, which exploits the fitness disadvantage displayed by drug-resistant cells in the absence of the drug, forestalls the onset of lethal drug-resistant disease. These data highlight the concept that drug-resistant cells may also display drug dependency, such that altered dosing may prevent the emergence of lethal drug resistance. Such observations may contribute to sustaining the durability of the vemurafenib response with the ultimate goal of curative therapy for the subset of melanoma patients with BRAF mutations.